To validate our siRNA screening findings, we treated A375 human melanoma cells with five distinct siRNAs targeting PKN1 and then assayed the expression of the β-catenin-activated reporter in the presence or absence of exogenous WNT3A. This evidence concerns the gene PKN1 and melanoma.